Clinical Trial Search block Test
An Open-Label Extension Study to Assess the Long-Term Safety And Efficacy Of Dupilumab In Patients ≥6 Months To <18 Years Of Age With Atopic Dermatitis
1434_OLE
What is the goal of the study?
This is a phase 3, open-label extension study investigating the long-term safety, efficacy, PK, and immunogenicity of repeat monthly SC doses of dupilumab in pediatric patients with AD who have previously completed a clinical study with dupilumab in patients with AD.
Who can participate in the study?
Everyone